Here are the S-3 shelf registrations from Pyxis Oncology, Inc. (PYXS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow PYXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PYXS filings page.
Pyxis Oncology, Inc. (PYXS) has filed a resale shelf registration covering up to 39,200,306 shares of common stock for selling stockholders. This consists of 19,600,153 Initial Shares issued in a July 2, 2026 private placement and 19,600,153 Common Warrant Shares issuable upon exercise of accompanying warrants.
The company will not receive proceeds from stockholder resales, but could receive up to $64.0 million in gross proceeds if the Common Warrants are exercised in full for cash; the warrants are exercisable at $3.289 per share and may also be exercised on a cashless basis. The private placement itself raised approximately $50 million in gross proceeds at $2.551 per share. Shares outstanding were 83,408,050 as of August 19, 2026.
Pyxis is a clinical-stage oncology company focused on solid tumors, with lead ADC candidate MICVO in Phase 1 studies for recurrent and metastatic head and neck squamous cell carcinoma, both as monotherapy and in combination with KEYTRUDA. Pyxis qualifies as an emerging growth company and a smaller reporting company. The most recent audited financial statements, incorporated by reference, include an auditor’s explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern.
Pyxis Oncology, Inc. has filed a shelf registration statement allowing it to offer up to $350,000,000 of securities, including common stock, preferred stock, debt, warrants, rights and units, over time. The specific terms and prices of each issuance will be set in future prospectus supplements.
Within this shelf, Pyxis also established an at-the-market program under which it may sell up to $150,000,000 of common stock from time to time through Leerink Partners, which will act as sales agent and receive up to 3.0% of the gross proceeds. Net proceeds from any sales are expected to be used for general corporate purposes such as working capital, operating expenses and capital expenditures, and potentially for complementary acquisitions.
Pyxis is a clinical-stage oncology company focused on solid tumors, particularly head and neck squamous cell carcinoma, and remains an emerging growth and smaller reporting company, which permits reduced public reporting requirements.